Jul 2026· Journal of Immunology· Vol 215· 0 citations
TL;DR
Results show IL1α as a regulator of mitochondrial metabolism and myeloid differentiation and a potential therapeutic target in breast cancer.
Abstract
Breast cancer remains one of the most prevalent and deadly malignancies worldwide. The tumor microenvironment (TME) critically shapes tumor progression and immune regulation through cytokine signaling. Among these, interleukin-1 alpha (IL1α) is a key mediator of breast cancer—associated immunosuppression. We initially identified IL1α produced by CX3CR1+ macrophage subset within the TME. Deletion of IL1α reduced tumor growth and depleted this population, suggesting IL1α-driven myeloid reprogramming. We hypothesize that IL1α deficiency reprograms myeloid differentiation from monocyte-derived suppressive macrophages to inflammatory macrophage.
An in vitro bone marrow—derived macrophage (BMDM) model from wild-type (WT) and IL1α knockout (KO) mice was used to assess IL1α-dependent differentiation. Flow cytometry and qPCR characterized CD11b+CD11c+MHCII+ subsets and quantified inflammatory (iNOS, CD80) versus inhibitory (Arginase-1, CD206) markers. Functional assays, including T-cell proliferation and MDSC activity, evaluated immunoregulatory capacity. Seahorse analysis and mass spectrometry assessed mitochondrial metabolism and electron transport chain (ETC) integrity.
IL1α KO BMDMs showed reduced F4/80 and CX3CR1 expression, a shift from CD11b+CD11c+MHCII^low to MHCII^high cells upon LPS activation, decreased inhibitory markers, and elevated inflammatory mediators. These macrophages exhibited reduced T-cell suppression and MDSC activity. Neutralization of extracellular IL1α in WT cells did not reproduce KO effects, supporting an intracellular role. IL1α loss impaired oxidative phosphorylation, and peptide inhibitor blocking IL1α mitochondrial localization reproduced this phenotype.
Our results show IL1α as a regulator of mitochondrial metabolism and myeloid differentiation. By stabilizing the ETC, IL1α sustains immunosuppressive macrophages, whereas its loss promotes inflammatory, anti-tumor myelopoiesis, identifying IL1α as a potential therapeutic target in breast cancer.
n/a
Innate Immune Responses and Host Defense: Molecular Mechanisms (INM)
Background Immune checkpoint inhibitors have improved outcomes for a subset of patients with non-small cell lung cancer (NSCLC), but the immunosuppressive tumor microenvironment (TME) limits their efficacy. Polarization of tumor-associated macrophages (TAMs) toward an M2 phenotype is a key feature of immune escape in N...
Q. Zheng, Binbing Qin, Bin Shen et al.· Frontiers in Cell and Develo...· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy defined by stromal desmoplasia, inflammation, and an immunosuppressive tumor microenvironment (TME) enriched for innate immune cells and characterized by effector T-cell dysfunction. Beyond malignant epithelial cells, the PDAC TME is composed predominantl...
Andrew Adams, H. Amirian, C. Rafie et al.· Cancer Research· 0 citations
Flow cytometry demonstrated that IL-33-IL1RAP signaling selectively induced CXCR2 expression and CXCR2-dependent trafficking in IL1RAP-competent J774M cells, a critical determinant of CXCR2-dependent neutrophil trafficking in PDAC.
Harper M. Marsh, Andrew Adams, H. Amirian et al.· Cancer Research· 0 citations
Tumor-associated macrophages (TAMs) are key regulators of the breast tumor microenvironment and often display immunosuppressive functions that limit cellular immunotherapy efficacy. Triggering receptor expressed on myeloid cells 2 (TREM2) has emerged as a modulator of myeloid cell activity and a potential target to e...
Jassaud Marius, Ziane-Chaouche Lydia, Raffo-Romero Antonella et al.· Cancer Immunology and Immuno...· 0 citations